Lamb Weston Holdings, Inc. (LW)
NYSE: LW · Real-Time Price · USD
57.07
-1.63 (-2.78%)
Jul 31, 2025, 4:00 PM - Market closed
Orchard Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Orchard Therapeutics stock have a consensus rating of "Buy" and an average price target of $68.91, which forecasts a 20.75% increase in the stock price over the next year. The lowest target is $56 and the highest is $85.
Price Target: $68.91 (+20.75%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Orchard Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 7 | 7 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $61 → $68 | Buy | Maintains | $61 → $68 | +19.15% | Jul 25, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $65 → $66 | Buy | Maintains | $65 → $66 | +15.65% | Jul 24, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $65 | Buy | Maintains | $70 → $65 | +13.90% | Jul 9, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $60 → $56 | Hold | Maintains | $60 → $56 | -1.87% | Jun 18, 2025 |
| Barclays | Barclays | Buy Maintains $69 → $61 | Buy | Maintains | $69 → $61 | +6.89% | May 12, 2025 |
Financial Forecast
Revenue This Year
6.62B
from 6.45B
Increased by 2.61%
Revenue Next Year
6.83B
from 6.62B
Increased by 3.23%
EPS This Year
3.55
from 2.50
Increased by 41.87%
EPS Next Year
3.94
from 3.55
Increased by 11.14%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 6.9B | 7.4B | 8.0B | |
| Avg | 6.6B | 6.8B | 7.3B | |
| Low | 6.1B | 6.4B | 6.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 7.5% | 12.2% | 17.4% | |
| Avg | 2.6% | 3.2% | 7.0% | |
| Low | -5.7% | -3.7% | -2.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.95 | 4.29 | 4.70 |
| Avg | 3.55 | 3.94 | 4.56 |
| Low | 2.84 | 3.47 | 4.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 57.9% | 21.1% | 19.3% |
| Avg | 41.9% | 11.1% | 15.8% |
| Low | 13.7% | -2.2% | 8.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.